$8.55
+5.4%Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
President, Chief Executive Officer & Director
Compensation
$2,759,410
Senior Vice President & Chief Compliance Officer
Senior Vice President & Chief Financial Officer
Compensation
$983,601
Senior Vice President & Chief Human Resources Officer
Senior Vice President & GM of Surgical
Senior Vice President of Operations
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$867,053
Vice President of Investor Relations & Treasurer
During the last 12 months, insiders have sold $312K worth of BVS shares, with no buying activity reported.
0
0.00
12.0K
105.44K
-105K
-$105K
0
0.00
0
0.00
+0
+$0
0
0.00
27.7K
206.91K
-207K
-$207K
0
0.00
0
0.00
+0
+$0
No buying activity
Mcmurry-Heath Michelle
Director
$237K
Nohra Guy P
Director
$76K
Strong bearish signal with $312K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
BVS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 22, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 22, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 17, 2022 | 2022 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.